In this section

Filter by year:

Events


Newsletters

Get in contact with us








Back

News & events

Loading loading...

  • Almirall and BioFocus enter research alliance


    Wed 25 Jan 2012
    Almirall, S.A. announced today that it has formed a research alliance with BioFocus, an affiliate from Galapagos NV (Euronext: GLPG).

    The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. Under the terms of the collaboration, BioFocus will apply its integrated drug discovery capabilities whilst Almirall will bring in respiratory specific knowhow to the joint experimental effort. The value of this collaboration to BioFocus could reach €7.5 million.

  • BioFocus creates novel diverse screening library


    Mon 05 Dec 2011
    BioFocus, an integrated drug discovery partner, today announced that it has enhanced its diverse screening library through new compound supply agreements with InterBioScreen, Enamine and ChemBridge. BioFocus now offers one of the most powerful screening platforms in the industry with over 900,000 unique chemical compounds and approximately 100,000 probes from natural sources.

  • Almirall and BioFocus announce collaboration to find new hit compounds against key targets


    Targets are related to the treatment of respiratory and inflammatory conditions
    Tue 15 Nov 2011
    Barcelona, Spain, and Saffron Walden, UK, November 15, 2011. The pharmaceutical company Almirall S.A. and BioFocus, an integrated drug discovery partner, today announced they have entered into a collaboration agreement to find new hit compounds against key targets of interest to Almirall.

  • BioFocus announces second extension to collaboration with Chiesi


    Wed 12 Oct 2011
    BioFocus announced today that it has extended its collaboration with Chiesi Farmaceutici, a privately owned Italian pharmaceutical company, for a second time. This extension of the collaboration with Chiesi is valued at €2.8 million.

  • Argenta and BioFocus announce two-year extension of drug discovery collaboration with Genentech


    Thu 18 Aug 2011
    Galapagos NV (Euronext: GLPG) announced today that its service division Argenta has extended its integrated contract drug discovery agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). Total potential value of the contract extension is up to £21.5 million (€23.4 million).

  • BioFocus and InterMed Discovery announce Marketing Collaboration


    Tue 19 Jul 2011
    BioFocus, an integrated drug discovery service partner, and InterMed Discovery GmbH (IMD), a natural product lead-discovery company, today announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed.

  • BioFocus enters collaboration with Michael J. Fox Foundation


    Wed 13 Jul 2011
    BioFocus announced today that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease. Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test.

  • BioFocus extends collaboration with Usher III Initiative


    Tue 21 Jun 2011
    BioFocus announced today that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision.

  • Evotec acquires compound management business from Galapagos


    Wed 01 Jun 2011
    Evotec AG (Frankfurt Stock Exchange: EVT; TecDAX) and Galapagos NV (Euronext: GLPG) today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, a Galapagos Company.




  • Astellas Pharma and BioFocus sign target discovery agreement


    Thu 12 May 2011
    BioFocus announced today that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders. Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.




Bookmark with:

What are these?


Print to HTML Print as PDF Send to a friend



BioFocus®, SoftFocus®, Galapagos®, SilenceSelect® and FLeXSelect® ThemePair™, FieldFocus™, HDRA™. Helical Domain Recognition Analysis™, 2D Roadmap™, Thematic Analysis™, SFK™, SFI™, SFG™ and PrimePath™ are trademarks of Galapagos NV and/or its affiliates.